Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nifekalant for electrical storm
ChiCTR1900027499Phase 4Recruiting
- Sponsor
- Wuhan Asia Heart Hospital
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nifekalant in Electrical Storm (ES), ventricular tachycardia (VT), ventricular fibrillation (VF) and 1 more, sponsored by Wuhan Asia Heart Hospital. Primary endpoint: Treatment efficiency rate. Started Mar 2016; status: recruiting.
02
Drugs
nifekalant
03
Conditions
Electrical Storm (ES)ventricular tachycardia (VT)ventricular fibrillation (VF)arrhythmia
Beyond the preview
Go deeper on ChiCTR1900027499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027499.